ArticleJournal of gastrointestinal oncology2011
The role of taxanes in the management of gastroesphageal cancer.
Article in Journal of gastrointestinal oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).Nature communications · 2022Trial
- Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3).Esophagus : official journal of the Japan Esophageal Society · 2021Trial
- Drug resistance mechanisms in cancers: Execution of pro-survival strategies.Journal of biomedical research · 2024Article
- Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer.Cancer medicine · 2023Article
- Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma.Frontiers in oncology · 2023Article
- Article
- Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.Annals of translational medicine · 2021Article
- Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.Advances in therapy · 2020Article
- Gene regulatory network analysis with drug sensitivity reveals synergistic effects of combinatory chemotherapy in gastric cancer.Scientific reports · 2020Article
- Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.International journal of molecular sciences · 2019Article
- Improvement of anti-cancer drug efficacy via thermosensitive hydrogel in peritoneal carcinomatosis in gastric cancer.Oncotarget · 2017Article
- EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.Oncotarget · 2015Article
- Expression of Rab25 correlates with the invasion and metastasis of gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.Diagnostic pathology · 2013Article
- RKIP expression associated with gastric cancer cell invasion and metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Overexpression of ZEB1 associated with metastasis and invasion in patients with gastric carcinoma.Molecular and cellular biochemistry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upper gastrointestinal cancers commonly referred to as gastroesophageal carcinomas encompass cancers of the esophagus, stomach and gastroesophageal junction. Although the number of newly diagnosed cases of gastric cancer has decreased in the United States, the whole burden of upper gastrointestinal carcinomas on society remains significantly high, with only a small improvement in overall survival achieved over the past two decades. Traditionally, therapeutic agents used to treat gastroesophageal cancers have been platinums and fluoropyrimidines. Taxanes are di-terpenes produced by the plants of the genus Taxus (yews). As their name suggests, taxanes were first derived from natural sources, but now they are all synthesized artificially. Interfering with cellular microtubular function during cell division is the main mechanism of action for currently available taxanes. Since their introduction into therapeutic oncology, many different other taxane-derivatives have been manufactured and are being developed. Changing the formulation of the drug to improve delivery such as liposomal encapsulation, and target deliver with antibody-drug conjugation, as well as introducing new class of cytotoxic agents that can overcome taxane-resistance. The two most commonly used taxanes are paclitaxel and docetaxel. Taxane is a class of cytotoxic agents more commonly administered in patients with breast and lung cancers. However, the regulatory approval of docetaxel to treat patients with metastatic or advanced gastroesophageal cancers in 2006 established the role of taxanes in the management of upper gastroesophageal cancers. This paper will review the current data of taxanes in the management of patients with upper gastrointestinal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.